Ensysce Biosciences (ENSC) Projected to Post Quarterly Earnings on Tuesday

Ensysce Biosciences (NASDAQ:ENSC) is anticipated to post its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect Ensysce Biosciences to post earnings of ($0.73) per share and revenue of $1.90 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Ensysce Biosciences (NASDAQ:ENSC) last posted its earnings results on Monday, March 30th. The company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.51. Ensysce Biosciences had a negative return on equity of 426.62% and a negative net margin of 200.87%.The company had revenue of $1.88 million during the quarter, compared to the consensus estimate of $0.50 million. On average, analysts expect Ensysce Biosciences to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ensysce Biosciences Stock Up 1.9%

Shares of ENSC traded up $0.01 during midday trading on Tuesday, reaching $0.43. 73,054 shares of the stock were exchanged, compared to its average volume of 4,460,515. Ensysce Biosciences has a twelve month low of $0.31 and a twelve month high of $2.75. The company has a market cap of $3.94 million, a P/E ratio of -0.10 and a beta of 0.87. The stock’s 50 day simple moving average is $0.50 and its 200 day simple moving average is $1.05.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ENSC. Adage Capital Partners GP L.L.C. increased its position in shares of Ensysce Biosciences by 100.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock worth $138,000 after purchasing an additional 75,000 shares during the period. DRW Securities LLC increased its position in shares of Ensysce Biosciences by 42.4% in the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock worth $91,000 after purchasing an additional 29,336 shares during the period. Citadel Advisors LLC bought a new position in shares of Ensysce Biosciences in the third quarter worth $34,000. Finally, Virtu Financial LLC bought a new position in shares of Ensysce Biosciences in the third quarter worth $34,000. Institutional investors own 5.63% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ensysce Biosciences in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Ensysce Biosciences currently has an average rating of “Sell”.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.